Centre for Integrated Preclinical Drug Development

The Centre for Integrated Preclinical Drug Development (CIPDD) offers state-of-the art infrastructure required for bringing innovations into the drug development pathway facilitating candidate selection and optimisation that enable discovery researchers to progress their inventions across the 'Valley of Death' to the point where they will attract investment for commercialisation into products for improving human health.

CIPDD's is a leading GLP and ISO17025 (R&D) accredited provider of preclinical drug development capabilities and bioanalytical/ pharmacokinetic (ADME) support for clinical trials - with data generated accepted by the FDA, EMA and the Australian Regulator - TGA. In addition, CIPDD undertakes research and testing of new analgesics in a large number of validated in vivo models of pain - an area of specialist expertise and headed by Professor Maree Smith. 

All CIPDD/TetraQ staff and research higher degree students must adhere to the strict requirements of its quality system in order to ensure reproducibility and traceability of all research data. 
 

Since commencement of operations in May 2005, CIPDD/TetraQ has conducted more than 500 R&D contracts for >200 industry and academic clients in the life science sector.

Contact:  Prof Maree Smith

Email:  info@cipdd.uq.edu.au

Phone:  +61 07 3346 6232 or _61 07 3346 7398

Level 14, 330 Collins St

Melbourne 3000 VIC

Call

T: +61 (07) 3735 4433

©2019 Therapeutic Innovation Australia

Enabled by

NCRIS-PROVIDER-RGB-REV.png